B
Bull
Bull · 25%CYBN
$7.76
Scenario price
$8.280
+0.101 (+1.22%)At close
Loading chart…
- High
- 8.381
- Open
- 8.270
- VWAP
- 8.27
- Vol
- 717.70K
- Mkt Cap
- 200.95M
- Low
- 8.140
- Amount
- 5.93M
- EV/EBITDA, TTM
- -1.04
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Valuation Metrics
The current forward P/E ratio for Cybin Inc (CYBN) is -3.19, compared to its 5-year average forward P/E of -3.39.
Alphio AI Price Scenarios for CYBN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CYBN
Events Timeline
News
7.501-04Yahoo FinanceOrganigram Expands Investment in Phylos to $10 Million for Cannabis Genetics
8.512-31BenzingaCybin Inc Launches $100 Million Equity Program, Shares Drop 6.6%
5.012-31BenzingaVanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
8.512-30NewsfilterCybin Launches $100 Million ATM Equity Program to Support Growth
8.512-30Yahoo FinanceCybin (CYBN) Launches At-the-Market Equity Program for Fundraising
CYBN FAQ — answered by Alphio AI
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.